Evolus to Report Second Quarter Financial Results on July 31, 2024

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has announced it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET the same day to discuss the results, followed by a Q&A session.

Interested parties can participate in the conference call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or by connecting to the live webcast on the Investor Relations page of the Evolus website. A telephonic replay will be available after the call, and an archived webcast can be accessed on the company's website.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13747672. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme^®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^® and Nuceiva^®, are registered trademarks and Evolysse^™ is a trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme^® is a trademark of Symatese Aesthetics S.A.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717426159/en/

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

FAQ

When will Evolus (EOLS) report its Q2 2024 financial results?

Evolus (EOLS) will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.

How can investors participate in Evolus' (EOLS) Q2 2024 earnings call?

Investors can participate in Evolus' Q2 2024 earnings call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or by connecting to the live webcast on the Investor Relations page of the Evolus website at 4:30 p.m. ET on July 31, 2024.

Will there be a replay available for Evolus' (EOLS) Q2 2024 earnings call?

Yes, a telephonic replay of Evolus' Q2 2024 earnings call will be available by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13747672. An archived webcast will also be accessible on the Investor Relations page of the Evolus website.